Genprex, Inc. (GNPX) stock
GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.71+0.04 (+2.36%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
Genprex operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Genprex's operating income for the twelve months ending Jun 30, 2026 was -$15.84M. For fiscal 2025 it was -$15.52M. The highest annual figure on record is -$3.31M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.52M | – |
| FY2024 | Dec 31, 2024 | -$21.17M | – |
| FY2023 | Dec 31, 2023 | -$31.06M | – |
| FY2022 | Dec 31, 2022 | -$23.83M | – |
| FY2021 | Dec 31, 2021 | -$20.67M | – |
| FY2020 | Dec 31, 2020 | -$17.96M | – |
| FY2019 | Dec 31, 2019 | -$10.68M | – |
| FY2018 | Dec 31, 2018 | -$12.36M | – |
| FY2017 | Dec 31, 2017 | -$3.31M | – |
| FY2016 | Dec 31, 2016 | -$4.13M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.49M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.26M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.78M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.38M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.43M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.70M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.17M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.44M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.20M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.04M | – |
| Q1 FY2018 | Mar 31, 2018 | -$686.63K | – |
| Q4 FY2017 | Dec 31, 2017 | -$664.72K | – |
| Q3 FY2017 | Sep 30, 2017 | -$715.12K | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$751.30K | – |
| Q4 FY2016 | Dec 31, 2016 | -$999.07K | – |
| Q3 FY2016 | Sep 30, 2016 | -$719.86K | – |
See a number that looks wrong?